January 28, 2025

Spyros Papapetropoulos, M.D.
Chief Executive Officer
Neuphoria Therapeutics Inc.
100 Summit Dr.
Burlington, Massachusetts 01803

       Re: Neuphoria Therapeutics Inc.
           Registration Statement on Form S-3
           Filed January 24, 2025
           File No. 333-284512
Dear Spyros Papapetropoulos M.D.:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Chris Edwards at 202-551-6761 with any questions.



                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:   Theodore Ghorra